[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ivf\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ivf":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,32,0,25,[9,45,73,97,130,155,170,203,235,259,280,303,327,349,373,400,422,450,476,501,530,553,573,599,624],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100534480","artificial-cycle-with-or-without-gnrh-agonist-pre-treatment-for-frozen-embryo-transfer-in-adenomyosis-patients-100534480",false,"NCT06239376","Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients","The Effectiveness of the Two Different Endometrial Preparation Regimes for Frozen Embryo Transfer in Patients With Adenomyosis","FET-ADE","Inclusion Criteria:\n\n* Confirm diagnosis with adenomyosis by using transvaginal ultrasonography (MUSA consensus) and\u002For pelvic magnetic resonance imaging.\n* Age between 18 - 42\n* Undergo less or equal to three previous IVF cycles\n* Indicate for frozen embryo transfer\n* Agree to have not more than two day-3 embryo or one blastocyst (day-5 and day-6) transferred\n* Not participating in any other study\n\nExclusion Criteria:\n\n* Embryos from IVM cycle\n* Having uterine or adnexal abnormalities (e.g., intrauterine adhesions, unicornuate\u002F bicornuate\u002F arcuate uterus; unremoved hydrosalpinx, endometrial polyp, submucosal leiomyoma, or leiomyoma with endometrial cavity distortion)\n* Having contraindications for exogenous hormones administration: breast cancer, risks of venous thromboembolism\n* Embryos from the oocyte donation cycle.\n* Patients with a history of GnRH injection within three months, measured from the last GnRHa injection to the study screening date.","FEMALE","18 Years","42 Years",{"count":22,"type":23},222,"ESTIMATED","INTERVENTIONAL",[26],"NA","This randomized clinical trial aims to assess the comparative effectiveness of two distinct endometrial preparation protocols for frozen embryo transfer (FET) among women with adenomyosis undergoing IVF\u002FICSI. Specifically, it seeks to address the following key questions:\n\n1. Does the protocol involving the combination of GnRH agonist and letrozole for down regulation with exogenous steroids (GnRHa+AI - AC) result in a higher live birth rate compared to the use of exogenous steroids alone (AC) in women with adenomyosis undergoing frozen embryo transfer?\n2. What are the common side effects of the GnRHa+AI - AC regimen?\n\nEligible participants will undergo screening before endometrial preparation for FET, following which they will be randomly assigned to one of two groups: GnRHa+AI - AC or AC. In the GnRHa+AI - AC group, participants will be pre-treated with GnRH agonist and letrozole two months before endometrial preparation. After this period, participants will return for endometrial preparation, and any side effects resulting from the down regulation will be evaluated. In contrast, the AC group will receive standard treatment.",[29,30,31],"Adenomyosis","IVF","Frozen Embryo Transfer","RECRUITING","2026-06-27",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":36},"2024-02-19",{"date":40,"type":23},"2027-05-30",{"name":42,"class":43},"Mỹ Đức Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100513753","is-decreased-ovarian-reserve-related-to-an-increased-number-of-previous-early-miscarriages-100513753","NCT05969574","Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?","Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages? A Prospective Observational Study","Inclusion Criteria:\n\n1\\. All participants with at least 1 previous pregnancy, who are assessed in one of our clinics (ART Fertility Clinics Abu Dhabi, Al Ain, Dubai)\n\nExclusion Criteria:\n\n1. Severe male factor (azoospermia, cryptozoospermia, severe oligoasthenoteratozoospermia (OAT))\n2. Severe Endometriosis and adenomyosis based on positive anamnesis or ultrasound performed in our center during the first consultation\n3. Uterine abnormalities (e.g. fibroids, different degrees of uterine septum), diagnosed by ultrasound\n4. History of ovarian surgery, chemotherapy, or radiation therapy\n5. Known genetic disorder or chromosomal abnormality\n6. BMI \\>40Kg\u002Fm2\n7. Currently using hormonal contraception or hormone replacement therapy",{"count":53,"type":23},2059,"OBSERVATIONAL","This study aims to explore the potential correlation between decreased ovarian reserve and previous history of early miscarriage.",[57,58,59,30],"Infertility, Female","Miscarriage","Miscarriage, Recurrent",[61,62,30],"miscarriage","infertility","2026-06-22",{"date":65,"type":36},"2026-06-25",{"date":67,"type":36},"2023-09-09",{"date":69,"type":23},"2026-12-31",{"name":71,"class":43},"ART Fertility Clinics LLC",3,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":19,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":24,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":44},"100477715","sex-selection-of-human-spermatozoa-100477715","NCT05500573","Sex Selection of Human Spermatozoa","Inclusion Criteria:\n\n* Couples undergoing infertility treatment with IVF or insemination seeking gender specific offspring for medical and non medical reasons\n\nExclusion Criteria:\n\n* Severe male factor",true,"ALL","89 Years",{"count":83,"type":23},2000,[26],"This study aims to demonstrate a reliable method of selecting gender specific sperm. X-bearing spermatozoa and Y-bearing spermatozoa will be identified from the density gradient layers. The selected gender specimen will then be utilized for assisted reproductive fertilization- in vitro fertilization or intrauterine insemination which are routine standard of care procedures.",[87,30],"Infertility","2026-05-26",{"date":90,"type":36},"2026-05-29",{"date":92,"type":36},"2013-11-06",{"date":94,"type":23},"2029-12-31",{"name":96,"class":43},"Weill Medical College of Cornell University",{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":24,"phases":106,"briefSummary":107,"conditions":108,"keywords":116,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":44},"100629899","aromatherapy-for-mental-health-promotion-in-ivf-patients-100629899","NCT07480668","Aromatherapy for Mental Health Promotion in IVF Patients","Aromatherapy for Mental Health Promotion in In Vitro Fertilization Patients: a Randomized Clinical Trial","Inclusion Criteria:\n\n* Female gender, age over 18 years.\n* Diagnosis of infertility with indication for In Vitro Fertilization (IVF).\n* Patients on the waiting list at HC-UFMG.\n* Agreement not to practice other mind-body or herbal complementary therapies during the study.\n* DASS-21 screening score compatible with at least mild anxiety, stress, and\u002For depression.\n* No aversion to inhaling essential oil or synthetic lavender essence.\n\nExclusion Criteria:\n\n* Severe neurological, psychiatric, or clinical disorders (e.g., schizophrenia, severe depression) that prevent participation.\n* Use of medications that could confound the primary outcome (e.g., sleep medications, anxiolytics, antidepressants, neuroleptics) in the 30 days prior to or during the study.\n* Known allergy to lavender products.\n* Pregnancy during the study period.\n* Use of essential oils in the last 90 days.",{"count":105,"type":23},120,[26],"The experience of infertility can cause significant emotional instability, especially for patients awaiting In Vitro Fertilization (IVF) treatment, generating anxiety, stress, and depressive symptoms. This study is a randomized clinical trial assessing the effectiveness of aromatherapy in improving mental health and quality of life in women undergoing infertility treatment. 120 participants will be randomized into three groups (Intervention, Placebo, and Control). The intervention involves the inhalation of true lavender essential oil (Lavandula angustifolia) for four weeks.",[109,110,111,112,113,30,114,115,87],"Anxiety","Stress","Depression Disorder","Quality of Life","Aromatherapy","Complementary Therapies","Spirituality",[57,113,117,118,115,30,109,110,119,120],"Lavender Oil","Complementary Therapy","Depression","In Vitro Fertilization","2026-04-24",{"date":123,"type":36},"2026-04-29",{"date":125,"type":36},"2026-03-01",{"date":127,"type":23},"2026-12",{"name":129,"class":43},"Federal University of Minas Gerais",{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":24,"phases":139,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":44},"100631372","phase-3-effect-of-pentoxyfilline-on-endometrial-thickness-and-frozen-embryo-transfer-outcomes-100631372","NCT07499817","Effect of Pentoxyfilline on Endometrial Thickness and Frozen Embryo Transfer Outcomes","Inclusion Criteria:\n\n* as good quality day five frozen embryos.\n\nExclusion Criteria:\n\n* history of endocrine diseases,\n* history of any previous surgery that couldm compromise the integrity of endometrium,\n* cardiovascular, renal and liver diseases,","43 Years",{"count":138,"type":23},100,[140],"PHASE3","The aim of this work was to investigate the effect of different vasodilators as pentoxifylline in women with unexplained infertility using IVF",[143,30,87],"Embryo Transfer",[145,30],"thawed embryo","2026-03-25",{"date":148,"type":36},"2026-03-30",{"date":150,"type":36},"2023-10-01",{"date":152,"type":23},"2026-04-30",{"name":154,"class":43},"Beni-Suef University",{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":136,"enrollmentInfo":161,"targetDuration":4,"studyType":24,"phases":162,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":166,"startDateStruct":167,"completionDateStruct":168,"leadSponsor":169,"locationsCount":44},"100631371","phase-4-effect-of-tadalafil-on-endometrial-thickness-and-frozen-embryo-transfer-outcomes-100631371","NCT07499804","Effect of Tadalafil on Endometrial Thickness and Frozen Embryo Transfer Outcomes","Inclusion Criteria:\n\n* has good quality day five frozen embryos.\n\nExclusion Criteria:\n\n* hypotension (blood pressure less than 90\u002F50) and\n* history of stroke or myocardial infarction",{"count":138,"type":23},[163],"PHASE4","investigate the effect of different vasodilators as Tadalafil in women with unexplained infertility using IVF",[30,57],{"date":148,"type":36},{"date":150,"type":36},{"date":152,"type":23},{"name":154,"class":43},{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":24,"phases":181,"briefSummary":182,"conditions":183,"keywords":186,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":201,"locationsCount":72},"100410056","biomarkers-of-endometrial-receptivity-100410056","NCT04619524","Biomarkers of Endometrial Receptivity","Biomarkers of Endometrial Receptivity: A Prospective Multicenter Study on Proteomic Biomarkers of Endometrial Receptivity in Cervical Mucus ( PRO BIOMER - CM )","BIOMER","Inclusion Criteria - Arm A - stimulated cycle:\n\n* female aged less than 37 years (maximally 36y + 364d)\n* no smoker\n* normal menstrual cycles lasting between 25 to 35 days\n* had been infertile for less than five years\n* normal responder\n* fewer than three failed cycles of assisted reproduction treatment, including fresh IVF\u002F intracytoplasmic sperm injection (ICSI) embryo transfer cycles and\u002For frozen-thawed embryo transfer cycles\n* sperm obtained through ejaculation\n* spermiogram more than 5 million sperm\u002FmL\n* BMI 19-29 kg\u002Fm2\n* follicle stimulating hormone (FSH) \\\u003C 10 IU\u002FL on the third day\n* basal antral follicle count of 5-15\n* undergoing the same routine gonadotrophin-releasing hormone agonist (GnRHa) long depot or gonadotrophin-releasing hormone antagonist (GnRH-ant.) protocol\n* informed consent\n\nExclusion Criteria - Arm A - stimulated cycle:\n\n* genetic disease\n* metabolic and\u002For endocrine disorders\n* polycystic ovary syndrome (defined by the Rotterdam criteria)\n* women with prior diagnosis of endometriosis or adenomyosis\n* previous gynecological\u002Fpelvic surgery except for salpingectomy\n* repeated spontaneous abortions (two or more)\n* previously less than 5 oocytes and\u002For serum anti-Mullerian hormone value \\\u003C 1.0 mIU\u002Fml or more than 20 oocytes, milli-International unit (mIU)\n* previous ovarian hyperstimulation syndrome (OHSS)\n* presence of any structural abnormality of the reproductive system\n* donor oocyte cycles\n* severe male factor infertility \\\u003C 5 million sperm\u002FmL\n* low response to stimulation\n* endometrium \\\u003C 8 mm at the day of human chorionic gonadotropin (hCG) or ET\n* number of retrieved oocytes 5 - 20\n* low fertilization capacity (rate of fertilization \\\u003C 20% and late ICSI following IVF fertilization failure)\n* OHSS\n* IVF cycle cancelled before ET\n* other than easy one high-quality blastocyst transfer (at least grade 3BB)\n\nInclusion criteria - Arm B - substituted cycle:\n\n* female aged less than 37 years (maximally 36y + 364d)\n* no smoker\n* normal menstrual cycles lasting between 25 to 35 days\n* had been infertile for less than five years\n* normal responder at stimulation\n* fewer than three failed cycles of assisted reproduction treatment, including fresh IVF\u002F intracytoplasmic sperm injection (ICSI) embryo transfer cycles and\u002For frozen-thawed embryo transfer cycles\n* sperm obtained through ejaculation\n* spermiogram more than 5 million sperm\u002FmL\n* BMI 19-29 kg\u002Fm2\n* FSH \\\u003C 10 IU\u002FL on the third day\n* undergoing the same routine estrogen\u002Fprogesterone substituted cycle\n* informed consent\n\nExclusion criteria - Arm B - substituted cycle:\n\n* genetic disease\n* metabolic and\u002For endocrine disorders such as diabetes, metabolic syndrome, and thyroid disorders\n* polycystic ovary syndrome (defined by the Rotterdam criteria), hyperprolactinaemia\n* women with prior diagnosis of endometriosis or adenomyosis\n* previous gynecological\u002Fpelvic surgery except for salpingectomy\n* repeated spontaneous abortions (two or more)\n* previously less than 5 oocytes and\u002For serum anti-Mullerian hormone value \\\u003C 0.5 mIU\u002Fml in the stimulated cycle\n* previous OHSS\n* presence of any structural abnormality of the reproductive system\n* severe male factor infertility \\\u003C 5 million sperm\u002FmL in the stimulated cycle\n* number of retrieved oocytes 5 - 20 in the stimulated cycle\n* low fertilization capacity (rate of fertilization \\\u003C 20% and late ICSI following IVF fertilization failure)\n* endometrium less than 8 mm at the day of thawing and transfer indication\n* thawed blastocyst cycle cancelled before ET\n* other than easy one best quality frozen\u002Fthawed blastocyst transfer (at least grade 3BB)","36 Years",{"count":180,"type":23},476,[26],"Analysis of proteins from cervical mucus will be done in patients undergoing infertility treatment (fresh or frozen embryo transfer). Cervical mucus will be analysed for potential new biomarkers of endometrium receptivity. Comparison of the peptide spectrum will be done for the pregnant and not pregnant patients.",[30,184,185,143],"Infertility Treatment","Fertility Disorders",[187,188,189,190,191,192,62,193,194],"cervix","mucus","endometrium","receptivity","biomarker","proteomics","in-vitro","fertilisation","2026-03-19",{"date":197,"type":36},"2026-03-20",{"date":199,"type":36},"2018-05-01",{"date":69,"type":23},{"name":202,"class":43},"The Institute of Molecular and Translational Medicine, Czech Republic",{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":24,"phases":212,"briefSummary":213,"conditions":214,"keywords":220,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":44},"100624916","the-effect-of-a-four-week-hatha-yoga-intervention-to-improve-quality-of-life-anxiety-and-depressive-symptoms-in-individuals-undergoing-assisted-reproductive-technology-art-treatment-100624916","NCT07415850","The Effect of a Four-Week Hatha Yoga Intervention to Improve Quality of Life, Anxiety, and Depressive Symptoms in Individuals Undergoing Assisted Reproductive Technology (ART) Treatment","The Effect of a Four-Week Hatha Yoga Intervention to Improve Quality of Life, Anxiety, and Depressive Symptoms in Individuals Undergoing Assisted Reproductive Technology (ART) Treatment: A Randomized Controlled Trial","Inclusion Criteria:\n\n* 18 years of age or older\n* Understand English\n* Scheduled for or currently undergoing an IVF cycle\n* Access to smartphone\u002Fcomputer\u002Ftablet and internet\n* Have a valid working email address\n\nExclusion Criteria:\n\n* Individuals who are Pregnant, or who become Pregnant during the study\n* Individuals undergoing non-IVF cycles (i.e. intrauterine insemination)\n* Individuals undergoing a frozen embryo transfer (FET) cycle\n* Individuals who are currently regularly practicing yoga\n* Individuals who score in the \"severe depression\" classification on the PHQ-9 (PHQ-9 score of 20-27)\n* Individuals endorsing suicidal ideation (answering yes on #9 of PHQ-9).",{"count":211,"type":23},80,[26],"The goal of this clinical trial is to learn if a four-week yoga program works to improve quality of life in people undergoing IVF (In Vitro Fertilization). It will also learn if a four-week yoga program decreases anxiety and depression symptoms in people undergoing IVF.\n\nThe main questions it aims to answer are:\n\n* Does a four-week yoga program effect quality of life, anxiety, and depression symptoms in people undergoing IVF?\n* Do the effects vary by individual characteristics of the people in the study?\n\nResearchers will compare the yoga intervention group to routine care as usual.\n\nParticipants will:\n\n* Participate in a weekly virtual yoga class for four weeks (total of four yoga classes), or follow routine care as usual while undergoing IVF.\n* Take three online surveys every 4 weeks.\n* Be involved in the study for 8 weeks.",[30,120,215,109,216,217,218,219],"Quality of Life (QOL)","Depression and Anxiety Symptom","Assisted Reproduction Technologies","Yoga","Mental Health",[221,222,112,223,218,224,114],"Fertilization in Vitro","Reproductive Techniques, Assisted","Psychological Well-Being","Mind-Body Therapies","NOT_YET_RECRUITING","2026-02-09",{"date":228,"type":36},"2026-02-17",{"date":230,"type":23},"2026-01-21",{"date":232,"type":23},"2027-01-31",{"name":234,"class":43},"Villanova University",{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":79,"sex":18,"minAge":19,"maxAge":243,"enrollmentInfo":244,"targetDuration":246,"studyType":54,"phases":4,"briefSummary":247,"conditions":248,"keywords":249,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":44},"100620969","non-invasive-preimplantation-genetic-screening-for-aneuploidies-and-clinical-outcomes-in-egg-donation-patients-100620969","NCT07364526","Non-Invasive Preimplantation Genetic Screening for Aneuploidies and Clinical Outcomes in Egg Donation Patients","Non-invasive Preimplantation Genetic Screening (niPGTA) in Oocyte Donation Patients.","niPGTAdon","Inclusion Criteria:\n\n* Women between 18 and 50 years old who are oocyte recipients.\n* Signed consent form\n* Transfer of a single blastocyst-stage embryo\n* Male with normal sperm FISH\n\nExclusion Criteria:\n\n* Uterine malformations\n* Abnormal karyotypes in either partner\n* Failure to sign informed consent","50 Years",{"count":245,"type":23},164,"3 Years","Preimplantation genetic testing for aneuploidies (PGT-A) is commonly used in IVF but requires embryo biopsy and shows limited benefit in egg donation cycles. Non-invasive PGT-A (niPGTA), based on the analysis of cell-free embryonic DNA in spent culture media, offers a promising biopsy-free alternative. This prospective, blinded study in egg donation cycles will evaluate whether niPGTA-detected aneuploidy is associated with implantation failure and pregnancy loss, assessing its potential clinical value as a non-invasive embryo selection tool.",[30],[250],"niPGTA",{"date":252,"type":36},"2026-01-23",{"date":254,"type":23},"2026-02-26",{"date":256,"type":23},"2027-12-01",{"name":258,"class":43},"Instituto Bernabeu",{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":243,"enrollmentInfo":266,"targetDuration":268,"studyType":54,"phases":4,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":4},"100612364","progesterone-levels-and-frozen-embryo-transfer-outcomes-100612364","NCT07252622","Progesterone Levels and Frozen Embryo Transfer Outcomes","PLATO","Inclusion Criteria:\n\n1. Signed informed consent\n2. Female patient undergoing programmed frozen embryo transfer using exogenous estrogen and progesterone, with exogenous progesterone administered via a combination of vaginal progesterone (Endometrin®) (2-3 times daily) and intermittent progesterone-in-oil (PIO) (every 3rd day) according to standard protocol. Protocols involving other formulations of vaginal progesterone (e.g. Crinone®, Prometrium®, will also be included).\n3. Planned transfer one 1 euploid embryo. Recruited patients will have at least 1 euploid embryo available for transfer.\n4. Standard eligibility criteria to undergo frozen embryo transfer at Shady Grove Fertility.\n5. 18 years and older\n\nExclusion Criteria:\n\n1. Age less than 18 years or greater than 51 years\n2. Planned intervention based on serum progesterone concentration measured any time after initiation of intramuscular or vaginal progesterone.\n3. Uterine cavity abnormality that has not been surgically corrected.\n4. Any medical or surgical contraindication to undergoing programmed frozen embryo transfer or pregnancy.\n5. Planned use of embryos cryopreserved by slow-freeze, prior to blastocyst stage, or other than PGT-A normal.\n6. Currently breast feeding, pregnancy, or having a contraindication to pregnancy.\n7. Participation in any experimental drug study within 60 days prior to screening.",{"count":267,"type":23},659,"9 Months","Frozen embryo transfers (FET) now represent the majority of all embryo transfer cycles, and upwards of 60% live births in United States are now attributable to frozen embryo transfers (1). Exogenous progesterone for endometrial decidualization and luteal phase support is thought to be critical to both optimizing endometrial receptivity for implantation as well as sustaining early pregnancy prior to reliable secretory activity of the early placenta.\n\nThe purpose of this study is to:\n\n1. Determine the prevalence of low serum progesterone levels (less than 10 ng\u002Fml) among patients undergoing a programmed embryo transfer cycle on the day of frozen embryo transfer.\n2. Determine if serum progesterone \\\u003C 10 ng\u002Fml on the day of frozen embryo transfer is associated with poorer FET outcomes: ongoing pregnancy (primary outcome), live birth, biochemical pregnancy, and clinical pregnancy.",[30],"2025-11-19",{"date":273,"type":36},"2025-11-28",{"date":275,"type":23},"2025-12-01",{"date":277,"type":23},"2028-11-01",{"name":279,"class":43},"Shady Grove Fertility Reproductive Science Center",{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":24,"phases":290,"briefSummary":291,"conditions":292,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":44},"100599757","single-step-protocol-and-multi-step-warming-protocol-for-blastocyst-fet-100599757","NCT07088640","Single Step Protocol and Multi-step Warming Protocol for Blastocyst FET","The Live Birth Rate Between Single and Multi-step Warming Protocol Applied in Blastocyst Vitrification: a Randomized Controlled Trial","ONESTEP","Inclusion Criteria:\n\n* Women aged from 18\n* Undergoing no more than 3 previous IVF\u002FICSI cycles\n* Had at least a single good-quality blastocyst frozen.\n* Endometrium preparation using artificial cycle\n* Agree to single blastocyst transfer\n* Not participating in any interventional studies at the same time\n\nExclusion Criteria:\n\n* Embryos from cycles after in-vitro maturation, pre-implantation genetic testing (PGT)\n* Having contraindications for exogenous hormone administration (e.g., breast cancer, thromboembolic disease)\n* Having uterine abnormalities (e.g., adenomyosis, intrauterine adhesions, unicornuate\u002F bicornuate\u002F arcuate uterus; unremoved hydrosalpinx or endometrial polyp)",{"count":289,"type":23},816,[26],"The multi-step thawing protocol with a reduction of non-permeable cryoprotectant concentrations to reduce osmotic shock caused by the rapid influx of water. Recent studies have shown that a simplified warming protocol by only a thawing solution gave a comparable survival rate but increased pregnancy rate, reduced patients' waiting time, and decreased the workload of embryologists.",[30,293,294],"Frozen Embryo Transfer (FET)","Embryo Thawing Protocol","2025-09-10",{"date":297,"type":36},"2025-09-12",{"date":299,"type":36},"2025-08-13",{"date":301,"type":23},"2027-03-01",{"name":42,"class":43},{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":80,"minAge":4,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":311,"conditions":312,"keywords":314,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":44},"100399183","follow-up-with-preimplantation-genetic-testing-patients-100399183","NCT04477863","Follow-up With Preimplantation Genetic Testing Patients","Inclusion Criteria:\n\n* Patients indicating willingness to participate in research during informed consent to perform PGT\n\nExclusion Criteria:\n\n* Patients who opted out of participating in research during informed consent to perform PGT",{"count":310,"type":23},10000,"The main purpose of this study is to perform longitudinal evaluations of clinical outcomes and personal perspectives following utilization of preimplantation genetic testing (PGT). Patients indicating willingness to participate in research during informed consent to perform PGT will be eligible for inclusion. A licensed genetic counselor will conduct a recorded interview.",[87,313,30],"Genetic Disease",[315,316],"PGT","Follow-up","2025-08-19",{"date":319,"type":36},"2025-08-26",{"date":321,"type":36},"2020-07-11",{"date":323,"type":23},"2050-12-31",{"name":325,"class":326},"Genomic Prediction Inc.","INDUSTRY",{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":334,"enrollmentInfo":335,"targetDuration":4,"studyType":24,"phases":337,"briefSummary":338,"conditions":339,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":44},"100539511","immediate-versus-postponed-single-blastocyst-transfer-in-programmed-or-stimulated-cycle-frozen-embryo-transfer-100539511","NCT06304792","Immediate Versus Postponed Single Blastocyst Transfer in Programmed or Stimulated Cycle Frozen Embryo Transfer","Immediate Versus Postponed Single Blastocyst Transfer in Programmed or Stimulated Cycle Frozen Embryo Transfer: a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Eligible for FET in a programmed- or stimulated cycle immediately following a fresh embryo transfer or freeze all cycle\n* Oligo-anovulatory women (cycle length \\> 35 days)\n* Ovulatory women (cycle length 21-35 days)\n* At least one vitrified day 5 or 6 blastocyst with Gardner score of ≥ 3BB at the day of vitrification\n\nExclusion Criteria:\n\n* Uterine malformation\n* Presence of hydrosalpinx, submucosal uterine myomas or uterine polyps\n* Allergies or contraindication to standard fertility medication\n* Male or female HIV or Hepatitis B or C\n* Preimplantation genetic testing (PGT) in the fresh cycle\n* Testicular sperm aspiration (TESA)\n* Severe OHSS with hospital admission and ascites drainage during the fresh cycle\n* Oocyte donation","40 Years",{"count":336,"type":23},484,[26],"The aim of this randomized controlled trial is to examine whether single blastocyst transfer in the first cycle after oocyte retrieval (immediate) is non-inferior to single blastocyst transfer in a subsequent cycle (postponed) in stimulated or programmed cycle frozen embryo transfer (FET). The primary outcome is live birth rate.",[87,30],"2025-08-05",{"date":342,"type":36},"2025-08-11",{"date":344,"type":36},"2024-02-01",{"date":346,"type":23},"2028-08-01",{"name":348,"class":43},"Rigshospitalet, Denmark",{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":334,"enrollmentInfo":356,"targetDuration":4,"studyType":24,"phases":358,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":372},"100592781","phase-2-menopur-and-rekovelle-combination-study-version-20-100592781","NCT06997900","Menopur And Rekovelle Combination Study Version 2.0","MARCS 2","Inclusion Criteria:\n\n* Women aged 18 to 40 years inclusively at the time of consent form signature\n* Diagnosis of unexplained infertility, tubal infertility, endometriosis stage I\u002FII or male factor infertility\n* Regular menstrual cycles of 24-35 days\n* Presence of both ovaries\n* Early follicular phase FSH serum concentration \\\u003C10 IU\u002FL measured between Day 2 and Day 5 of menstrual cycle within the previous 24 months\n* First IVF\u002FICSI cycle\n* IVF antagonist protocol prescribed\n* Partner or donor ejaculated sperm (fresh or frozen) used for fertilization\n\nExclusion Criteria:\n\n* Women undergoing oocyte donation\n* Endometriosis stage III\u002FIV\n* High risk of OHSS (AMH ≥ 35 pmol\u002FL)\n* Body Mass Index (BMI) \\> 40 kg\u002Fm2 Protocol number: IIS-1056 MARCS 2.0 Study Version: 1.1 - Date : 14 APR 2025 Page 12 of 28\n* Gynaecological haemorrhages of unknown aetiology\n* History of recurrent miscarriages defined as ≥ 3 consecutive losses\n* Renal or hepatic impairment\n* Hypersensitivity to any active ingredient or excipients in follitropin delta and\u002For HP-hMG\n* Tumours of hypothalamus or pituitary gland\n* Ovarian enlargement or ovarian cyst not due to polycystic ovarian syndrome\n* Current or history of ovarian, uterine or mammary carcinoma\n* History of thrombophilia\n* Use of hormonal preparations (except for 17β-estradiol, testosterone gel, DHEA and thyroid medication) during the last menstrual cycle\n* Women participating in any other interventional research project",{"count":357,"type":23},200,[359],"PHASE2","The goal of this clinical trial is to evaluate the safety and effectiveness of a personalized ovarian stimulation regimen in women aged 18 to 40 undergoing in vitro fertilization (IVF). The main question it aims to answer is:\n\n\\- Does personalizing the starting doses of follitropin delta (REKOVELLE) and HP-hMG (MENOPUR) based on both age and body lead to similar results as anti-Müllerian hormone (AMH) and weight based dosing ?\n\nResearchers will compare the new dosing regimen to the MARCS study results to see if this new approach leads to similar outcomes\n\nParticipants will:\n\n* Receive ovarian stimulation using a personalized dose of REKOVELLE aND MENOPUR based on age and weight\n* Be monitored through ultrasound imaging and blood tests to measure estradiol (E2) levels\n* Undergo standard IVF procedures including egg retrieval and embryo assessment",[30,362,185],"Controlled Ovarian Simulation","2025-07-29",{"date":365,"type":36},"2025-07-31",{"date":367,"type":36},"2025-07-04",{"date":369,"type":23},"2027-08",{"name":371,"class":326},"Clinique Ovo",2,{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":79,"sex":18,"minAge":19,"maxAge":243,"enrollmentInfo":380,"targetDuration":4,"studyType":24,"phases":382,"briefSummary":383,"conditions":384,"keywords":385,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":44},"100498818","effect-of-intrauterine-administration-of-autologous-pbmc-modulated-with-ifnt-on-ivf-outcome-100498818","NCT05775198","Effect of Intrauterine Administration of Autologous PBMC Modulated With IFNt on IVF Outcome","Effects of Intrauterine Administration of Autologous Peripheral Blood Mononuclear Cells (PBMC) Immunomodulated With Interferon Tau (IFNt) Prior to Embryo Transfer on IVF Outcome","Inclusion Criteria:\n\n* Participating in Assisted Reproduction Treatment\n* Having primary infertility\n* Having regular menstrual cycles\n* Scheduled to undergo embryo transfer of euploid embryos only\n\nExclusion Criteria:\n\n* Uterine pathologies\n* Endometrial bacterial infections\n* Active endometrial inflammation\n* Polycystic ovary syndrome\n* Presence of auto antibodies such as anti-TPO (thyroid peroxidase), anti-TG (thyroglobulin), ACA (anticentromere antibodies), APA (antiphospholipid antibodies), ANA (antinuclear antibodies), and anti-dsDNA\n* Presence of mutations involving the coagulation system such as deficiency of factor XII, Pro C, Pro S\n* Oncological condition\n* Positive HIV (human immunodeficiency virus), HCV (hepatitis C virus) or HBV (hepatitis B virus) tests",{"count":381,"type":23},300,[26],"The goal of this clinical trial is to test the effect of modulated specialised immune cells isolated from the patients' own blood when administered to the uterus before embryo transfer on the IVF outcome (implantation, pregnancy and live birth rates).\n\nTo achieve this, blood will be obtained from eligible participants. Target cells will be isolated and incubated with the tested modulator for 24h, and returned to the uterine cavity 1 day prior to embryo transfer.\n\nResearchers will compare the reproductive outcome of the tested intervention to that of a control group who will not receive the investigated cell treatment prior to embryo transfer.",[57,30],[386,387,388,389,390],"intrauterine PBMC","interferon tau","implantation","clinical pregnancy","live birth rate","2025-05-20",{"date":393,"type":36},"2025-05-21",{"date":395,"type":36},"2023-03-01",{"date":397,"type":23},"2026-04-28",{"name":399,"class":43},"Nadezhda Women's Health Hospital",{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":407,"enrollmentInfo":408,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":409,"conditions":410,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":44},"100590748","endometrioma-ethanol-sclerotherapy---prospective-cohort-study-protocol-100590748","NCT06971458","Endometrioma Ethanol Sclerotherapy - Prospective Cohort Study Protocol","Endometrioma Ethanol Sclerotherapy and Its Effect on Ovarian Function and Fertility Treatment Outcome - Prospective Cohort Study Protocol","Inclusion Criteria:\n\nA woman with endometrioma with a diameter of 25-100 mm\n\nExclusion Criteria:\n\n* Other causes of infertility (sperm disorder, ovulation disorder, uterine disorder, mechanical factor, poor ovarian reserve)","41 Years",{"count":105,"type":23},"Ovarian endometriomas are cystic masses lined with endometrial tissue that contains fluid arising from a collection of menstrual debris. Ovarian endometriomas clinical manifestations includes pelvic pain, dysmenorrhea, dysfunctional uterine bleeding, and infertility.\n\nEndometriomas are most commonly treated either medically or by surgical excision.\n\nUltrasonography (US)-guided aspiration and sclerotherapy is a new approach. Its mechanism of action is believed to be destruction of the inner epithelial lining, which is followed by inflammation and fibrosis, eventually resulting in regression of the cyst. The main advantage in this approach is the avoidance of collateral damage to the ovary.",[30,411],"Endometrioma","2025-05-06",{"date":414,"type":36},"2025-05-14",{"date":416,"type":36},"2022-08-09",{"date":418,"type":23},"2027-12-31",{"name":420,"class":421},"Hillel Yaffe Medical Center","OTHER_GOV",{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":18,"minAge":429,"maxAge":430,"enrollmentInfo":431,"targetDuration":4,"studyType":24,"phases":433,"briefSummary":434,"conditions":435,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":44},"100557955","trial-to-evaluate-the-clinical-utility-of-non-invasive-endometrial-receptivity-test-ora-in-patients-with-implantation-failure-100557955","NCT06544837","Trial to Evaluate the Clinical Utility of Non-invasive Endometrial Receptivity Test (Ora) in Patients With Implantation Failure","Multi-national, Multi-center, Randomized Controlled Trial to Evaluate the Clinical Utility of Non-invasive Endometrial Receptivity Test (Ora) in Patients With Implantation Failure","Inclusion Criteria:\n\n* Experienced implantation failure with euploid or low-level mosaic (\\\u003C 30%) embryos in the past two years.\n* Female age 28-45 years.\n* Consent to undergo a simulated cycle for non-invasive optimal implantation window testing.\n* Plan to undergo a frozen embryo transfer cycle.\n* Have at least one euploid or low-level mosaic (\\\u003C 30%) frozen blastocyst.\n\nExclusion Criteria:\n\n* Presence of uterine cavity abnormalities that may affect implantation, such as polyps, fibroids ≧4 cm, or hydrosalpinx\n* Presence of systemic diseases that may affect reproductive techniques (e.g., autoimmune diseases)\n* Body mass index (BMI) over 30 kg\u002Fm²","28 Years","45 Years",{"count":432,"type":23},1000,[26],"The adjustment of the timing of embryo transfer based on the endometrial receptivity profile and transferring embryo(s) of good quality with normal chromosomes (diagnosed by Preimplantation Genetic Testing for Aneuploidy, PGT-A) are the two main causes to improve the success of assisted reproduction treatments (ART). Previously, endometrial receptivity analysis was performed on women undergoing IVF treatment through an invasive endometrial tissue biopsy. The aim of this study is to determine the clinical benefits of ORA, a novel non-invasive endometrial receptivity test that determines the optimal time for embryo transfer through a blood draw instead of an invasive endometrial tissue biopsy. It is expected to recruit 1000 couples whose embryos will be analyzed by PGT-A and\u002For who are going to evaluate their endometrium expression profile for endometrial receptivity. The patients will be randomized into two groups, (1) Control group : undergoing PGT-A only; (2) Study group : the undergoing both PGT-A and ORA. ART will be performed based on the results of PGT-A and\u002For ORA. Reproductive success, such as implantation rates (IR), pregnancy rates (PR), ongoing pregnancy rates (OGP) and live birth rates (LBR) will be tracked and compared.\n\nPreliminary results demonstrate that both PGT-A and ORA can contribute to reproductive success, improving implantation rates in patients with implantation failure. Our hypothesis suggests that PGT-A and ORA could improve the performance of ART in infertile patients.",[30,436,437,438,439,440],"Window of Implantation","microRNA","Implantation","Non-invasive Testing","Endometrial Receptivity","2025-05-04",{"date":443,"type":36},"2025-05-07",{"date":445,"type":36},"2024-06-22",{"date":447,"type":23},"2027-06-01",{"name":449,"class":326},"Inti Labs",{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":79,"sex":18,"minAge":457,"maxAge":136,"enrollmentInfo":458,"targetDuration":4,"studyType":24,"phases":460,"briefSummary":461,"conditions":462,"keywords":463,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":44},"100558780","phase-2-ubiquinone-vs-ubiquinol-supplementation-100558780","NCT06555575","Ubiquinone vs. Ubiquinol Supplementation","A Randomized Controlled Trial of Ubiquinone vs Ubiquinol Supplementation in Women Over Age 37 Undergoing in Vitro Fertilization.","Inclusion Criteria:\n\n1. Women age \\>37 and \\\u003C43 years undergoing their first in vitro fertilization (IVF) cycle\n2. Day 3 follicle-stimulating hormone (FSH) \\\u003C12 IU\u002FL with serum estradiol \\\u003C250 pmol\u002FL and normal thyroid-stimulating hormone (TSH) and Prolactin\n3. Partner with semen analysis suitable for IVF or ICSI\n4. Anti-müllerian hormone (AMH) \\> 3 pmol\u002FL\n5. Be willing and able to provide written informed consent for the study.\n6. Be an otherwise healthy female and considered eligible by the investigator to be treated with a daily dose of 225 IU Recombinant human FSH (recFSH) and 75 IU Human menopausal gonadotrophins (hMG).\n7. Documented history of infertility for at least 12 months before randomization (not applicable in case of tubal infertility or severe male factor infertility, or when the use of donor sperm is indicated)\n8. Have a body mass index (BMI) ≥17.5 and ≤38 kg\u002Fm2\n9. Have available ejaculatory sperm (use of donated and\u002For cryopreserved sperm is allowed)\n10. Have a normal uterine cavity (no evidence of uterine polyp or submucosal fibroid) as assessed by either saline-infused sonohysterography or by hysteroscopy within 12 months of randomization\n11. Have results of clinical laboratory tests (hematology, serum chemistry, and urinalysis) within normal limits or clinically acceptable to the investigator\n12. Has a pelvic ultrasound showing no cyst ≥15 mm\n\nExclusion Criteria:\n\n1. Has been diagnosed with or treated for any endocrine abnormality within 3 years prior Note: Participants with a history of clinical or subclinical hypothyroidism may be eligible if thyroid stimulating hormone levels at screening are within normal limits and the participant has been on a stable dose of thyroid replacement medication (or on no replacement therapy) for at least 8 weeks.\n2. Has a prolactin level above the upper limit of normal for the central laboratory\n3. Has FSH \\>12.0 IU\u002FL\n4. Has a history of a full or partial resection of an ovary, including a history of ovarian cystectomy, or of any ovarian tumors limiting access to the ovary during ovum pick-up, e.g., endometriomas or teratomas measuring \\>10 mm\n5. Has unilateral or bilateral hydrosalpinx that communicates with the endometrial cavity on screening ultrasound or hysterosalpingography.\n6. Has intramural fibroids ≥3 cm or submucosal fibroids of any size\n7. Has Asherman's syndrome (untreated) or endometrial polyps that have not been resected\n8. Has any congenital uterine abnormality which is associated with a decreased chance of pregnancy\n9. Inadequate visualization of 1 or both ovaries\n10. One or both ovaries not accessible for oocyte retrieval\n11. Has a history of recurrent pregnancy losses (i.e., \\>3 pregnancy losses)\n12. Has a history or current evidence of human immunodeficiency virus (HIV) Note: Results obtained within 1 year prior to signing the informed consent form are considered valid.\n13. Has tumors of the ovary, breast, uterus, pituitary, or hypothalamus\n14. Has a history of epilepsy, thrombophilia, diabetes, untreated or inadequately treated subclinical hypothyroidism, clinically significant cardiovascular, gastrointestinal, hepatic, renal, pulmonary, or auto-immune disease requiring treatment within the last 3 years\n15. Is a current smoker who smokes ≥5 cigarettes per day\n16. Is assessed by the Investigator as unlikely or unable to adhere to dose and\u002For visit schedules","37 Years",{"count":459,"type":23},90,[359],"The objective of this study is to determine if ubiquinol will result in improved reproductive outcomes in older women at a reduced oral dose compared to current standard treatment with ubiquinone.",[30],[464,465,466],"ubiquinone","ubiquinol","reproductive outcome","2025-04-07",{"date":469,"type":36},"2025-04-10",{"date":471,"type":36},"2025-01-23",{"date":473,"type":23},"2027-01",{"name":475,"class":43},"Trio Fertility",{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":18,"minAge":482,"maxAge":430,"enrollmentInfo":483,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":485,"conditions":486,"keywords":487,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":44},"100486359","confounding-factors-of-chronic-endometritis-in-women-with-reproductive-failure-100486359","NCT05613049","Confounding Factors of Chronic Endometritis in Women With Reproductive Failure","Inclusion criteria:\n\n1. Age 20-45 years;\n2. Women with a history of 2 or more consecutive miscarriages before 24 weeks of gestation12; or\n3. Women who failed to conceive after unprotected intercourse for one year; or\n4. Women who failed failure to achieve a clinical pregnancy after two consecutive cycles of IVF, ICSI or frozen embryo replacement cycles where the cumulative number of transferred embryos is no less than four for day-2 embryos and no less than 2 for day-5 embryos (blastocysts), with all embryos being of good quality.\n\nExclusion criteria\n\n1. Uncorrected uterine anomalies, such as the septate or bicornuate uterus, fibroids (submucous\u002Fintramural);\n2. Untreated hydrosalpinx;\n3. History of antiphospholipid syndrome;\n4. Known clinical autoimmune disease;\n5. Undergoing immunotherapy;\n6. Abnormal thyroid function;\n7. Abnormal karyotyping.\n8. Those with active pelvic inflammatory disease or suspicion of infection etc.","20 Years",{"count":484,"type":23},720,"The aim of the study is to investigate the confounding factors of chronic endometritis and therapeutic benefits of antibodies targeting plasma cells in women with reproductive failure.",[30],[488,489,490,62,30,491],"chronic endometritis","confounding factors","reproductive failure","infertility women","2025-03-26",{"date":494,"type":36},"2025-03-27",{"date":496,"type":36},"2023-01-26",{"date":498,"type":23},"2028-01-31",{"name":500,"class":43},"Chinese University of Hong Kong",{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":80,"minAge":4,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":24,"phases":510,"briefSummary":511,"conditions":512,"keywords":515,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":529,"locationsCount":44},"100508153","a-novel-integrative-non-invasive-embryo-selection-approach-for-ivf-based-on-mk-rs-analysis-100508153","NCT05896709","A Novel Integrative Non-invasive Embryo Selection Approach for IVF Based on MK-RS Analysis","A Novel Integrative Non-invasive Embryo Selection Approach for in Vitro Fertilization Based on Artificial Intelligence Enhanced Morphokinetic Analysis and Raman Spectra in Spent Culture Media","Inclusion Criteria:\n\n1. Patients undergoing IVF\u002F ICSI treatment\n2. Patients receiving the first, second or third IVF\u002FICSI treatment cycle\n3. Patients and their partners willing to sign the informed consent agreement\n4. Patients having at least three normal fertilised embryos on the day of the fertilization check\n5. Consecutive women undergoing IVF treatment\n6. Patients planning to use a time-lapse incubator for embryo culture\n\nExclusion Criteria:\n\n1. Day one human embryos with blur imaging\n2. Large obstructions in the embryo area\n3. More than half of the embryo area is blocked by the well or degeneration\n4. Patients with more than half of the embryos without sufficient spent culture medium for RS analysis\n5. Patients with known genetic diseases",{"count":509,"type":23},176,[26],"During assisted reproductive technology treatment, embryo selection is an important process that may affect the clinical pregnancy rate. Many assisted reproductive technology units over the world have tried different approaches to increase the clinical pregnancy rate. Conventionally, the morphology of the embryo is assessed by the embryologist with naked eyes only. Nowadays, artificial intelligence (AI) has been used to assist in morphological assessment of the embryo. Our pilot study showed that the AI-enhanced morphokinetic (MK) analysis increased the accuracy in embryo selection by \\~9%, while the detection rate for abnormal chromosomes in embryo has also been increased by Raman spectroscopy (RS) analysis. The combined MK-RS analysis will be able to complete embryo assessment within 5-6 days after fertilization. This method needs shorter time and is at lower cost when compared to invasive preimplantation genetic testing for aneuploidies (PGT-A).\n\nIn this study, we have combined the following non-invasive techniques to assist in embryo screening.\n\n1. Using time-lapse imaging (i.e. images of embryo being taken every 10 minutes inside the incubator) with AI)-enhanced MK analysis to assess the entire morphological changes of the embryo.\n2. As the embryo releases metabolites during its growth, the spent culture medium will be collected after culture of the embryo and then be used for RS analysis, which is a kind of metabolomics-based non-invasive PGT-A, for screening chromosomal abnormalities of the embryo.\n\nThis study will include two phases. In Phase I, it is a retrospective part. We will collect data to train the convolutional neural network (CNN)-enhanced MK with RS method on embryo selection, leading to the integrated approach (MK-RS). In Phase II, it is a randomized controlled trial and participants will be randomised into 2 groups. For the experimental group, embryo selection will be based on the MK-RS method, whereas embryo selection for the control group will rely on the traditional embryo assessment results alone. Then we will assess the clinical pregnancy rate and evaluate the efficacy of our approach finally. Patients who receive in vitro fertilisation (IVF)\u002F intracytoplasmic sperm injection (ICSI) treatment from The Assisted Reproductive Technology (ART) Unit of The Chinese University of Hong Kong, Prince of Wales Hospital will be recruited.",[513,514,30],"Reproductive Issues","Subfertility",[516,517,518,519,520,521,522],"non-invasive","in vitro fertilization","time-lapse imaging","artificial intelligence","morphokinetic analysis","Raman spectroscopy","embryo selection","2025-03-18",{"date":525,"type":36},"2025-03-21",{"date":527,"type":36},"2023-07-17",{"date":127,"type":23},{"name":500,"class":43},{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":334,"enrollmentInfo":537,"targetDuration":4,"studyType":24,"phases":539,"briefSummary":541,"conditions":542,"keywords":4,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":4},"100582972","early-phase-1-comparison-of-pregnancy-rates-in-modified-natural-frozen-embryo-transfer-fet-cycle-after-luteal-support-with-gnrh-agonist-versus-progesterone-100582972","NCT06870266","Comparison of Pregnancy Rates in Modified Natural Frozen Embryo Transfer (FET) Cycle After Luteal Support with GnRH Agonist Versus Progesterone","Comparison of Pregnancy Rates in Modified Natural Frozen Embryo Transfer (FET) Cycle After Luteal Support with GnRH Agonist Versus Progesterone: Prospective Randomized Study","Inclusion Criteria:\n\n1. Women treated at the Shaare Zedek IVF clinic scheduled for frozen embryo transfer\n2. Normo-ovulatory women\n3. Women undergoing frozen embryo transfer in a modified natural cycle\n4. BMI 18-35\n5. Age 18-40\n\nExclusion Criteria:\n\n1. Women undergoing medicated FET cycles\n2. BMI \\>35 or \\\u003C18\n3. Women with hydrosalpinx\n4. Women with congenital or acquired uterine anomalies (e.g., myomas)\n5. Egg donation or surrogacy\n6. Women with endometriosis\n7. Intolerance to GnRH agonists\n8. Nasal congestion or respiratory conditions affecting nasal absorption",{"count":538,"type":23},150,[540],"EARLY_PHASE1","Background:\n\nThe capability to transfer frozen embryos reduces embryo loss following in vitro fertilization (IVF) and results in higher pregnancy rates compared to a single IVF cycle.\n\nEndogenous progesterone from the corpus luteum, following frozen embryo transfer in natural or modified natural cycles, is expected to provide sufficient luteal support, as observed in spontaneous pregnancies. Nevertheless, research has demonstrated higher pregnancy success rates with additional luteal support. The current standard for luteal phase support involves vaginal progesterone administration.\n\nSeveral case reports have indicated that administering a gonadotropin-releasing hormone (GnRH) agonist during the luteal phase does not compromise pregnancy continuation achieved through IVF and may, in fact, enhance implantation success.\n\nStudies have shown that the luteal phase can be maintained with a GnRH agonist alone, without the need for progesterone supplementation.\n\nA recent prospective randomized controlled trial compared standard progesterone support with GnRH agonist support in fresh embryo transfers. The group receiving GnRH agonist support demonstrated a significantly higher pregnancy rate.\n\nGiven the studies proving the positive impact of GnRH agonist, there is a need for a prospective randomized controlled trial to evaluate the use of GnRH agonist support in frozen embryo transfers.\n\nAims and Significance:\n\nThis study aims to compare pregnancy rates between women receiving GnRH agonist treatment and those receiving standard progesterone-based luteal support during frozen embryo transfers in natural cycles as part of IVF treatments.\n\nConducting a prospective comparative study will enable us to assess the effectiveness of GnRH agonist treatment relative to standard luteal phase support. Based on the results, the investigators may consider treatment with intranasal GnRH agonist, which improves quality of life and may also enhance pregnancy and live birth rates.\n\nMethods:\n\nThe study will be conducted on patients scheduled to undergo modified natural cycles. Participants will be randomly allocated into two groups:\n\n1. Study Group: Luteal phase support will begin on the day of ovulation with Nafarelin nasal spray (200 mcg twice daily) for two weeks, until pregnancy blood test (hCG).\n2. Control Group: Luteal phase support will be provided through vaginal progesterone. Endometrin 100 mg twice daily. If the hCG test is positive, the supportive treatment will continue until the 8th week of pregnancy, as per the attending physician's instructions.\n\nClinical follow-up will include monitoring for clinical pregnancy outcomes, miscarriage rates, and live births.",[543,293],"Ivf","2025-03-05",{"date":546,"type":36},"2025-03-11",{"date":548,"type":23},"2025-03",{"date":550,"type":23},"2027-06",{"name":552,"class":43},"Shaare Zedek Medical Center",{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":334,"enrollmentInfo":560,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":562,"conditions":563,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":44},"100392462","is-there-a-role-for-mechanical-stimulation-in-ovarian-follicular-activation-100392462","NCT04390308","Is There A Role For Mechanical Stimulation In Ovarian Follicular Activation?","Is There A Role For Mechanical Stimulation In Ovarian Follicular Activation? A Randomized Control Trial.","Inclusion Criteria:\n\n* Signed and dated informed consent\n* Women 40 years of age and younger with documented primary ovarian insufficiency (12).\n* Normal Karyotype\n* BMI \\\u003C\u002F= 35 kg\u002Fm2\n* Oligo\u002Famenorrhea for at least 4 months\n* FSH \\> 25 IU\u002FmL\n* AMH \\\u003C\u002F= 0,1 ng\u002Fml\n* No evidence of follicles \\> 4mm\n* Must have two ovaries of approximately equal volume.\n* Willingness to undergo further fertility treatment, including IVF if there is evidence of response\n* A transvaginal scan including Doppler for arteria ovarica will be performed previously to the surgical procedure.\n\nExclusion Criteria:\n\n* Premature ovarian failure due to a genetic origin, such as Turner's Syndrome or chromosomal abnormality.\n* Oncological diseases (specially, skeletal system and blood).\n* Autoimmune diseases, for example, lupus erythematosus, etc.\n* Previous treatments including radiotherapy or chemotherapy.\n* Other conditions not suitable for surgical procedures and\u002For anesthesia.\n* Anticoagulant or antiaggregant treatment.\n* Acute and chronic infectious diseases.\n* Active substance abuse or dependence.\n* Major Mental health disorder.",{"count":561,"type":23},70,"Premature ovarian failure (POI) is a loss of normal function before age 40, leading to infertility and hypoestrogenism. About 1% of women younger than 40 years old and 0.1% before 30 are affected. Most patients already had impaired or complete loss of fecundity when diagnosed. Hence, the treatment of POI is particularly tough. Currently, no optimal regimen exists to ameliorate ovarian function.",[57,564,30],"Premature Ovarian Failure","2025-02-17",{"date":567,"type":36},"2025-02-19",{"date":569,"type":36},"2021-06-02",{"date":571,"type":23},"2025-12-31",{"name":71,"class":43},{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":577,"acronym":578,"eligibilityCriteria":579,"healthyVolunteers":79,"sex":80,"minAge":19,"maxAge":334,"enrollmentInfo":580,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":582,"conditions":583,"keywords":587,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":72},"100541756","cardiometabolic-function-in-offspring-mother-and-placenta-after-assisted-reproductive-technology-100541756","NCT06334003","Cardiometabolic Function in Offspring, Mother and Placenta After Assisted Reproductive Technology","COMPART","Inclusion Criteria:\n\nPregnant women who have either had fertility treatment at Rigshospitalet or Herlev Hospital (FET and fresh ET groups) or are scheduled for prenatal ultrasounds at Rigshospitalet or Herlev Hospital (NC group) will be screened for eligibility. Inclusion must happen before their routine ultrasound scan in 1. trimester.\n\nExclusion Criteria:\n\n* Maternal pregestational diabetes type 1 or 2\n* Non-singleton pregnancies\n* Maternal pregestational BMI \\> 35 kg\u002Fm2\n* Severe maternal co-morbidity\n* Oocyte donation",{"count":581,"type":23},600,"The overall objective is to establish the first-of-its-kind longitudinal cohort of pregnant women, biological fathers\u002Fpartners and offspring from pregnancies achieved by frozen embryo transfer (FET), fresh-embryo transfer (fresh ET) and naturally conceived (NC) to investigate maternal cardiometabolic profiles, fetal growth patterns and placental function during pregnancy as well as metabolic and endocrine health in the offspring. Additionally, the aim is to explore genetic and epigenetic patterns in placenta, fetus and parents. As secondary objectives, the investigator group will examine telomere length and minipuberty hormones in children born after FET, fresh-ET and NC.",[584,30,585,586],"ART","Children, Only","Cardiovascular Disease Other",[588,589,590,30],"Frozen embryo transfer","Cardiovascular","Metabolic","2024-11-20",{"date":593,"type":36},"2024-11-25",{"date":595,"type":36},"2024-05-17",{"date":597,"type":23},"2027-01-01",{"name":348,"class":43},{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":4,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":18,"minAge":482,"maxAge":20,"enrollmentInfo":606,"targetDuration":4,"studyType":24,"phases":608,"briefSummary":609,"conditions":610,"keywords":611,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":44},"100566081","levofloxacin-plus-metronidazole-suppositories-versus-levofloxacin-co-administered-with-metronidazole-tablets-in-chronic-endometritis-100566081","NCT06650540","Levofloxacin Plus Metronidazole Suppositories Versus Levofloxacin Co-administered with Metronidazole Tablets in Chronic Endometritis","Levofloxacin Plus Metronidazole Suppositories Versus Levofloxacin Co-administered with Metronidazole Tablets for the Treatment of Chronic Endometritis: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Infertile patients aged 20-42 years\n* Hysteroscopy and endometrial biopsy were performed, and the\n* Pathological diagnosis was chronic endometritis\n* Serum FSH level on the second day of menstruation was ≤12U\u002FL\n* Agree and sign the informed consent form\n\nExclusion Criteria:\n\n* Patients with the following diagnoses: submucosal myoma; Uterine malformation or previous surgery for correction of uterine deformity; Intrauterine adhesions; The previous history of pelvic tuberculosis or endometrial tuberculosis or the current pathology suggested endometrial tuberculosis; Endometrial hyperplasia or endometrial cancer\n* Patients with spouse, previous fetal or child chromosomal abnormalities who plan to undergo preimplantation genetic screening\n* Patients with a history of allergy to study drugs",{"count":607,"type":23},800,[26],"This is a single randomised controlled trial. The investigators plan to randomise 800 participants to the levofloxacin plus metronidazole suppositories versus levofloxacin co-administered with metronidazole tablets for the treatment of chronic endometritis in a 1:1 rate. Primary outcome will be the live birth rate after the embryo transfer.",[30],[612,613,614],"Chronic Endometritis","pregnancy outcomes","pharmacological treatment","2024-10-18",{"date":617,"type":36},"2024-10-21",{"date":619,"type":23},"2024-10-22",{"date":621,"type":23},"2026-12-30",{"name":623,"class":43},"Peking University Third Hospital",{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":630,"eligibilityCriteria":631,"healthyVolunteers":79,"sex":18,"minAge":19,"maxAge":334,"enrollmentInfo":632,"targetDuration":4,"studyType":24,"phases":634,"briefSummary":635,"conditions":636,"keywords":638,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":646,"completionDateStruct":648,"leadSponsor":650,"locationsCount":72},"100513231","ethanol-sclerotherapy-prior-to-art-100513231","NCT05962775","Ethanol Sclerotherapy Prior to ART","The Impact of Ethanol Sclerotherapy Before ART (Assisted Reproductive Technology) Cycle on Cumulative Live Birth Rate in Infertile Women With Endometrioma: A Randomized Controlled Trial","START","Inclusion Criteria:\n\n* AMH\\>0.3 ng\u002Fml\n* unilateral\u002Fbilateral endometrioma\n* Endometrioma diameter 40-100 mm\n\nExclusion Criteria:\n\n* 3 or more IVF\u002Fembryo transfer failure\n* Menstrual cycle abnormalities\n* Male Factor infertility\n* Presence of uterine fibroids\n* Presence of hydrosalpinx\n* Presence of uterine abnormalities\n* Suspicion of malignancy according to International Ovarian Tumor Analysis criteria",{"count":633,"type":23},84,[26],"The goal of this randomized controlled trial is to assess the impact of ethanol sclerotherapy on ART cycle outcomes. The main questions it aims to answer are:\n\n1. Does ethanol sclerotherapy before ART cycle has any impact on cumulative live birth rate in patients with endometrioma?\n2. Does ethanol sclerotherapy improve chronic pelvic pain, dysmenorrhea, complications during oocyte retrieval, response to ovarian stimulation (number of mature oocytes retrieved), and pregnancy loss rates?\n\nInfertile patients with endometrioma between 4-10 cm who are scheduled for ART within 2 cycles will be randomized to ethanol sclerotherapy or no intervention.",[411,87,637,584,30],"Sclerotherapy",[639,640,641,517,642],"endometrioma","ethanol sclerotherapy","assisted reproductive technology","cumulative live birth rate","2024-10-13",{"date":645,"type":36},"2024-10-16",{"date":647,"type":36},"2023-05-01",{"date":649,"type":23},"2026-04-01",{"name":651,"class":43},"Ankara University"]